Evidence map›Paper›PMID 39924751›Full record

ArticleAdvanced healthcare materials2025

3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline.

Xingyun Yang, Mara Artibani, Yongcheng Jin, Aneesh Aggarwal, Yujia Zhang, Sandra Muñoz-Galvan, Ellina Mikhailova, Lena Rai, Nobina Mukherjee, Ravinash Krishna Kumar and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xingyun YangDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Mara ArtibaniOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Yongcheng JinDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Aneesh AggarwalOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Yujia ZhangDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Sandra Muñoz-GalvanOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Ellina MikhailovaDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Lena RaiOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Nobina MukherjeeDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Ravinash Krishna KumarDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Ashwag AlbukhariBiochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Shaohua MaTsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen, 518055, China.
Linna ZhouDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.ORCID 0000-0002-1938-5428
Ahmed Ashour AhmedOvarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Hagan BayleyDepartment of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.

Funding

Cancer Research UKCancer Research UK Oxford Centre Development FundCancer Research UK's Pioneer Award Grant (CRUK)Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia 852European Research Council Advanced Grant (SYNTISU)European Research Council Proof of Concept Grant (BIOELECTRIC)Health Research Bridging Salary Scheme at the University of Oxford 0011044Ovarian Cancer ActionOxford Martin School Programme on 3D Printing for Brain RepairUniversity of Oxford Medical and Life Sciences Translational Fund
6 · The paper itself

Abstract

The poor survival of ovarian cancer patients is linked to their high likelihood of relapse. In spite of full apparent macroscopic clearance, tumor recurrences arise from cells that are resistant to primary chemotherapy in the form of minimal residual disease (MRD). MRD exhibits distinct molecular drivers from bulk cancer and therefore necessitates alternative therapeutic strategies. However, there is a lack of 3D models that faithfully recapitulate MRD ex vivo for therapy development. This study constructs microfluidics-based 3D microtumors to generate a clinically-relevant model for ovarian cancer MRD. The microtumors recapitulate the non-genetic heterogeneity of ovarian cancer, capturing the "Oxford Classic" five molecular signatures. Gene expression in the 3D microtumors aligns closely with MRD from ovarian cancer patients and features the upregulation of fatty acid metabolism genes. Finally, the MRD 3D microtumors respond to the approved fatty acid oxidation inhibitor, perhexiline, demonstrating their utility in drug discovery. This system might be used as a drug-testing platform for the discovery of novel MRD-specific therapies in ovarian cancer.

Indexed as

Fatty AcidsNeoplasm, ResidualOvarian NeoplasmsPerhexilineCell Line, TumorFemaleHumansOxidation-ReductionFatty AcidsPerhexiline3D cancer modelsdrug testing platformsmicrofluidicsminimal residual diseaseovarian cancer

Identifiers

PMID39924751
PMCPMC12118330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.